Outlook Therapeutics® Reports Financial Results for Sec

Upcoming Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023 for ONS-5010, an investigational ophthalmic formulation of bevacizumab for the...

Related Keywords

United States , Ukraine , United Kingdom , Russia , Japan , China , Harriet Ullman , Russell Trenary , Jenene Thomas , Lavoie Health Science , Committee For Medicinal Products Human Use , Amerisourcebergen , Outlook Therapeutics Inc , Nasdaq , Aji Bio Pharma Services , Fujifilm , Exchange Commission , Alliance Healthcare , Upcoming Prescription Drug User Fee Act , Outlook Therapeutics , License Application , Chief Executive Officer , Planning Underway , Support Potential Approval , First Ophthalmic Formulation , Pre Launch Preparations Proceeding , Marketing Authorization Application , Medicinal Products , Human Use , Syntone Biopharma , Special Protocol Assessments , Fiscal Second Quarter Ended March , Outlook Therapeutic , Annual Report , Quarterly Report , Nasdaq Otlk , Nc ,